三鑫医疗(300453) - 2024 Q4 - 年度业绩

Financial Performance - The total operating revenue for 2024 reached RMB 150,043.84 million, an increase of 15.41% compared to the previous year[4] - The net profit attributable to shareholders was RMB 22,731.95 million, reflecting a growth of 10.01% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 20,978.46 million, up by 15.97% from the previous year[4] - The basic earnings per share rose to RMB 0.4355, marking a 9.23% increase year-on-year[4] - The weighted average return on net assets was 17.80%, a slight decrease of 0.22% from the previous year[4] Assets and Equity - The total assets at the end of the reporting period amounted to RMB 222,248.96 million, representing a 9.44% increase from the beginning of the period[5] - The equity attributable to shareholders increased to RMB 132,398.12 million, a growth of 6.22% compared to the start of the period[5] Market Strategy - The company expanded its market share by leveraging precise market demand judgments and increasing overseas market presence[5] - The company achieved stable growth in revenue and net profit through cost reduction and efficiency enhancement strategies[5] Audit and Reporting - The financial data presented is preliminary and subject to change upon final audit in the annual report[7]